|
WO2004083432A1
(en)
*
|
2003-03-21 |
2004-09-30 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
CA2523672C
(en)
|
2003-04-29 |
2012-07-17 |
Avi Biopharma, Inc. |
Compositions for enhancing transport of molecules into cells
|
|
US20050222068A1
(en)
*
|
2003-10-23 |
2005-10-06 |
Mourich Dan V |
Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
|
|
US20050234002A1
(en)
*
|
2004-01-23 |
2005-10-20 |
Mourich Dan V |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
|
US20050288246A1
(en)
*
|
2004-05-24 |
2005-12-29 |
Iversen Patrick L |
Peptide conjugated, inosine-substituted antisense oligomer compound and method
|
|
EP3808845A1
(en)
|
2004-06-28 |
2021-04-21 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
US8129352B2
(en)
|
2004-09-16 |
2012-03-06 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating ssRNA viral infection
|
|
ES2852549T3
(es)
*
|
2005-02-09 |
2021-09-13 |
Sarepta Therapeutics Inc |
Composición antisentido para tratamiento de la atrofia muscular
|
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
|
US8524676B2
(en)
*
|
2005-09-08 |
2013-09-03 |
Sarepta Therapeutics, Inc. |
Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
|
|
US8168181B2
(en)
|
2006-02-13 |
2012-05-01 |
Alethia Biotherapeutics, Inc. |
Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
|
|
CA2638823A1
(en)
|
2006-02-13 |
2007-08-23 |
Alethia Biotherapeutics Inc. |
Polynucleotides and polypeptide sequences involved in the process of bone remodeling
|
|
US8785407B2
(en)
*
|
2006-05-10 |
2014-07-22 |
Sarepta Therapeutics, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
PT2203173E
(pt)
|
2007-10-26 |
2016-03-15 |
Academisch Ziekenhuis Leiden |
Resumo
|
|
CA2710013A1
(en)
*
|
2007-12-28 |
2009-07-09 |
Avi Biopharma, Inc. |
Immunomodulatory agents and methods of use
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US8231895B2
(en)
*
|
2008-05-22 |
2012-07-31 |
Universidade De Coimbra |
Targeted delivery to human diseases and disorders
|
|
US20110130346A1
(en)
*
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
EP2283029A1
(en)
|
2008-06-04 |
2011-02-16 |
Medical Research Council |
Peptides
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
CA3066050A1
(en)
|
2008-10-24 |
2010-04-29 |
Sarepta Therapeutics, Inc. |
Multiple exon skipping compositions for dmd
|
|
AU2009335740B2
(en)
*
|
2008-12-17 |
2016-04-21 |
Sarepta Therapeutics, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
|
ES2593836T3
(es)
|
2009-04-24 |
2016-12-13 |
Biomarin Technologies B.V. |
Oligonucleótido que comprende una inosina para tratar la DMD
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
SI2499249T1
(sl)
|
2009-11-12 |
2019-02-28 |
The University Of Western Australia, |
Protismiselne molekule in postopki zdravljenja patologij
|
|
BR112012011381B8
(pt)
|
2009-11-13 |
2021-05-25 |
Avi Biopharma Inc |
oligonucleotídeo antisenso antiviral isolado e composição farmacêutica compreendendo o mesmo
|
|
US20120309934A1
(en)
*
|
2009-12-11 |
2012-12-06 |
Gwangju Institute Of Science And Technology |
Intracelluar targeting bipodal peptide binder
|
|
WO2011127210A1
(en)
*
|
2010-04-06 |
2011-10-13 |
Massachusetts Institute Of Technology |
Targeted delivery of nucleic acids
|
|
US9050373B2
(en)
*
|
2010-05-13 |
2015-06-09 |
The Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
|
|
KR102095478B1
(ko)
|
2010-05-28 |
2020-04-01 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
DK3031920T3
(da)
*
|
2010-07-19 |
2019-10-14 |
Ionis Pharmaceuticals Inc |
Modulation af dystrofi myotonica-protein kinase (dmpk) ekspression
|
|
US8198429B2
(en)
|
2010-08-09 |
2012-06-12 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
|
US9161948B2
(en)
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
KR102339196B1
(ko)
*
|
2011-05-05 |
2021-12-15 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
펩타이드 올리고뉴클레오타이드 접합체
|
|
US9302014B2
(en)
|
2011-08-30 |
2016-04-05 |
Medical Research Council |
Cell-penetrating peptides having a central hydrophobic domain
|
|
WO2013033407A2
(en)
|
2011-08-30 |
2013-03-07 |
The Regents Of The University Of California |
Identification of small molecules that enhance therapeutic exon skipping
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
ES2535654T3
(es)
*
|
2011-10-13 |
2015-05-13 |
Association Institut De Myologie |
ADN triciclo-fosforotioato
|
|
US9326992B2
(en)
*
|
2011-12-08 |
2016-05-03 |
Sarepta Therapeutics, Inc. |
Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
|
|
CA2862628C
(en)
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
BR112014028631A2
(pt)
|
2012-05-16 |
2017-10-17 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão da família de genes da hemoglobina
|
|
DK2850186T3
(en)
*
|
2012-05-16 |
2019-04-08 |
Translate Bio Ma Inc |
COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
|
|
CA2873797A1
(en)
*
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating utrn expression
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
AU2013262699A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating ATP2A2 expression
|
|
CA2873779A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating mecp2 expression
|
|
KR101329411B1
(ko)
*
|
2012-05-31 |
2013-11-14 |
주식회사 엘지생활건강 |
피부투과성 펩타이드
|
|
CA2928851A1
(en)
|
2012-07-19 |
2014-01-23 |
Alethia Biotherapeutics Inc. |
Anti-siglec-15 antibodies
|
|
EP3626309B1
(en)
|
2012-08-13 |
2023-03-08 |
The Rockefeller University |
Lxrbeta agonist for the treatment of cancer
|
|
RU2018123569A
(ru)
|
2012-09-25 |
2019-03-07 |
Джензим Корпорейшн |
Связанные с пептидом морфолиновые антисмысловые олигонуклеотиды для лечения миотонической дистрофии
|
|
WO2014076196A1
(en)
|
2012-11-15 |
2014-05-22 |
Santaris Pharma A/S |
Anti apob antisense conjugate compounds
|
|
CN103981147B
(zh)
|
2013-02-08 |
2017-11-10 |
中国科学院上海生命科学研究院 |
一种新的制备肝实质细胞的方法
|
|
IL280443B
(en)
|
2013-03-14 |
2022-07-01 |
Sarepta Therapeutics Inc |
Preparations that skip axon for the treatment of muscular dystrophy
|
|
MX373959B
(es)
|
2013-03-15 |
2020-07-13 |
Sarepta Therapeutics Inc |
Composición para usarse en el tratamiento de la distrofia muscular de duchenne (dmd).
|
|
US10010562B2
(en)
|
2013-11-06 |
2018-07-03 |
Merck Sharp & Dohme Corp. |
Dual molecular delivery of oligonucleotides and peptide containing conjugates
|
|
EP3620178A3
(en)
|
2014-05-16 |
2020-07-22 |
Oregon State University |
Antisense antibacterial compounds and methods
|
|
US10391098B2
(en)
|
2014-05-19 |
2019-08-27 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
|
EP3795687A1
(en)
|
2014-05-23 |
2021-03-24 |
Genzyme Corporation |
Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
|
|
CN106459975B
(zh)
|
2014-05-23 |
2020-03-27 |
建新公司 |
肽载体上的多个寡核苷酸部分
|
|
JP6994941B2
(ja)
*
|
2014-12-31 |
2022-02-04 |
オレゴン ステート ユニバーシティ |
アンチセンス抗細菌性化合物および方法
|
|
MA41795A
(fr)
*
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
US11020417B2
(en)
|
2015-06-04 |
2021-06-01 |
Sarepta Therapeutics, Inc |
Methods and compounds for treatment of lymphocyte-related diseases and conditions
|
|
MA45819A
(fr)
*
|
2015-10-09 |
2018-08-15 |
Sarepta Therapeutics Inc |
Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
|
|
US10907158B2
(en)
|
2015-12-23 |
2021-02-02 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
|
AU2016379402B2
(en)
*
|
2015-12-23 |
2023-01-12 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
KR102522059B1
(ko)
|
2016-04-18 |
2023-04-14 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
안티센스 올리고머, 및 산성 알파-글루코시다제 유전자와 연관된 질환을 치료하기 위한 이의 사용 방법
|
|
SG11201809468XA
(en)
|
2016-04-29 |
2018-11-29 |
Sarepta Therapeutics Inc |
Oligonucleotide analogues targeting human lmna
|
|
MD3554553T2
(ro)
|
2016-12-19 |
2022-10-31 |
Sarepta Therapeutics Inc |
Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară
|
|
US10800817B2
(en)
*
|
2016-12-19 |
2020-10-13 |
Morehouse School Of Medicine |
Compositions and methods for treating diseases by inhibiting exosome release
|
|
MA65895B1
(fr)
*
|
2016-12-19 |
2024-06-28 |
Sarepta Therapeutics, Inc. |
Conjugués d'oligomères induisant le saut d'exons pour la dystrophie musculaire
|
|
DK3554552T3
(da)
|
2016-12-19 |
2022-10-24 |
Sarepta Therapeutics Inc |
Exon-skipping-oligomerkonjugater mod muskeldystrofi
|
|
WO2018129384A1
(en)
|
2017-01-06 |
2018-07-12 |
Avidity Biosciences Llc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
|
US20180207293A1
(en)
*
|
2017-01-25 |
2018-07-26 |
2C Tech Corp. |
Nanoparticles for sustained ophthalmic drug delivery and methods of use
|
|
GB201711809D0
(en)
*
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
US20210145852A1
(en)
|
2017-09-28 |
2021-05-20 |
Sarepta Therapeutics, Inc. |
Combination Therapies for Treating Muscular Dystrophy
|
|
EP3687519A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
US20200248178A1
(en)
|
2017-09-28 |
2020-08-06 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
TW202423453A
(zh)
*
|
2017-10-17 |
2024-06-16 |
美商薩羅塔治療公司 |
用於反義遞送之細胞穿透肽
|
|
EP3713575A4
(en)
|
2017-11-21 |
2021-08-25 |
Rgenix, Inc. |
POLYMORPHS AND THEIR USES
|
|
JP7013626B2
(ja)
*
|
2018-01-05 |
2022-02-01 |
国立医薬品食品衛生研究所長 |
細胞膜透過ペプチド、構築物、及び、カーゴ分子を細胞内に輸送する方法
|
|
WO2019217682A1
(en)
|
2018-05-09 |
2019-11-14 |
Ohio State Innovation Foundation |
Cyclic cell-penetrating peptides with one or more hydrophobic residues
|
|
EP3806868A4
(en)
|
2018-06-13 |
2022-06-22 |
Sarepta Therapeutics, Inc. |
EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
|
|
TW202449155A
(zh)
|
2018-07-27 |
2024-12-16 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CN112955154A
(zh)
*
|
2018-08-02 |
2021-06-11 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗强直性肌营养不良的用途
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
GB201812980D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
GB201812972D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
CN113453723A
(zh)
|
2018-12-07 |
2021-09-28 |
牛津大学科技创新有限公司 |
接头
|
|
JP7658900B2
(ja)
|
2018-12-13 |
2025-04-08 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
|
|
GB201821269D0
(en)
|
2018-12-28 |
2019-02-13 |
Nippon Shinyaku Co Ltd |
Myostatin signal inhibitor
|
|
JP2022528725A
(ja)
|
2019-04-18 |
2022-06-15 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを治療するための組成物
|
|
GB201911403D0
(en)
*
|
2019-08-09 |
2019-09-25 |
Univ Oxford Innovation Ltd |
Conjugate and uses thereof
|
|
KR102270700B1
(ko)
*
|
2019-11-01 |
2021-06-30 |
한국과학기술연구원 |
폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
|
|
PL4073025T3
(pl)
|
2019-12-13 |
2024-09-16 |
Inspirna, Inc. |
Sole metali i ich zastosowania
|
|
TWI874546B
(zh)
|
2019-12-26 |
2025-03-01 |
日商日本新藥股份有限公司 |
誘導外顯子５０的跳讀的反義核酸
|
|
AU2021226089A1
(en)
|
2020-02-28 |
2022-09-15 |
National Center Of Neurology And Psychiatry |
Antisense nucleic acid inducing skipping of exon 51
|
|
US11987795B2
(en)
|
2020-11-24 |
2024-05-21 |
The Broad Institute, Inc. |
Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
|
|
WO2022140535A1
(en)
|
2020-12-23 |
2022-06-30 |
Sarepta Therapeutics, Inc. |
Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
|
|
WO2022232478A1
(en)
|
2021-04-30 |
2022-11-03 |
Sarepta Therapeutics, Inc. |
Treatment methods for muscular dystrophy
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
KR20240024176A
(ko)
|
2021-06-23 |
2024-02-23 |
니뽄 신야쿠 가부시키가이샤 |
안티센스 올리고머의 조합
|
|
WO2023282345A1
(ja)
|
2021-07-08 |
2023-01-12 |
日本新薬株式会社 |
腎毒性軽減剤
|
|
CN118201606A
(zh)
|
2021-07-08 |
2024-06-14 |
日本新药株式会社 |
肾毒性减轻剂
|
|
AU2022306542A1
(en)
|
2021-07-08 |
2024-01-18 |
Nippon Shinyaku Co., Ltd. |
Precipitation suppressing agent
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
WO2023034515A2
(en)
*
|
2021-09-03 |
2023-03-09 |
Sarepta Therapeutics, Inc. |
Delivery of anitsense oligomers by mirror image peptides
|
|
IL315280A
(en)
|
2022-03-17 |
2024-10-01 |
Sarepta Therapeutics Inc |
Phosphorodiamidate morpholino oligomer conjugates
|
|
CN119183457A
(zh)
|
2022-04-15 |
2024-12-24 |
达因疗法公司 |
用于治疗强直性肌营养不良的肌肉靶向复合物和制剂
|
|
US20250289851A1
(en)
|
2022-04-22 |
2025-09-18 |
Entrada Therapeutics, Inc. |
Cyclic peptides for delivering therapeutics
|
|
WO2024091824A1
(en)
|
2022-10-26 |
2024-05-02 |
Ada Forsyth Institute, Inc. |
Differentiation and reprogramming of chondrocyte
|
|
EP4612292A1
(en)
|
2022-11-02 |
2025-09-10 |
Sarepta Therapeutics, Inc. |
Formulation of an antisense oligomer conjugate
|
|
WO2024129459A1
(en)
|
2022-12-16 |
2024-06-20 |
University Of Rochester |
Repairmen! of barrier dysfunction in esophagus
|
|
WO2025085868A2
(en)
|
2023-10-20 |
2025-04-24 |
Radiation Control Technologies, Inc. |
Cd47-targeting morpholinos
|